Oral Cladribine Will Not be an Option

Oral cladribine, a potential MS treatment in clinical trials, has been withdrawn from the FDA approval process.   Based on the CLARITY trial, cladribine reduced new MS attacks by 58% compared to placebo.  The FDA requested additional studies to be performed which could take several years.  Because of the probability of multiple other new treatments including oral options by that time,  Merck Serono has decided to finish the current trials but not to pursue approval by the FDA and similar organizations worldwide.  Cladribine tablets will no longer be available in Russia and Australia which had already Cladribine available to patients.